Free Trial

Sight Sciences (SGHT) FDA Events

Sight Sciences logo
$3.43 -0.09 (-2.56%)
Closing price 04:00 PM Eastern
Extended Trading
$3.44 +0.01 (+0.29%)
As of 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
FDA Events for Sight Sciences (SGHT)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Sight Sciences (SGHT). Over the past two years, Sight Sciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as TearCare. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

TearCare System - FDA Regulatory Timeline and Events

TearCare System is a drug developed by Sight Sciences for the following indication: Meibomian Gland Dysfunction (MGD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Sight Sciences FDA Events - Frequently Asked Questions

As of now, Sight Sciences (SGHT) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Sight Sciences (SGHT) has reported FDA regulatory activity for TearCare System.

The most recent FDA-related event for Sight Sciences occurred on December 19, 2024, involving TearCare System. The update was categorized as "Results," with the company reporting: "Sight Sciences, Inc. announced the results of a Budget Impact Analysis ("BIA") of the TearCare® System ("TearCare") for the treatment of MGD-associated dry eye disease ("DED") in the United States."

Currently, Sight Sciences has one therapy (TearCare System) targeting the following condition: Meibomian Gland Dysfunction (MGD).

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:SGHT) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners